(September 8, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has completed its inspection of the Company's Galway, Ireland facility, and that the FDA reported no observations. The inspection began September 1 and ended yesterday.

The Galway facility is one of two Boston Scientific facilities that manufacture the TAXUS™ Express²™ paclitaxel-eluting coronary stent system. The other is in Maple Grove, Minnesota. That facility was inspected by the FDA in July, and the agency reported no observations at the conclusion of that inspection as well.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and introduction, clinical trials, the regulatory process, competitive offerings, litigation, operational improvements, the Company's overall business strategy, and other factors described in the Company's filings with the Securities and Exchange Commission.